1-3 of 3
Rosmy B. John
Close
Sort by
Journal Articles

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias J. Jabbour, Zeev E. Estrov, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Graciela M. Nogueras González, Xiao Qin Dong, Stefan Faderl, Heather Schneider, Rosmy B. John, Meghan Anne Meyer, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 3674.
https://doi.org/10.1182/blood-2021-151493
Published: 2021
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-139942
Published: 2020
Journal Articles

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Naveen Pemmaraju, MD, Yesid Alvarado, MD, Maro N. Ohanian, DO, Rosmy B. John, MSN, Patrick S. Zbyszewski, MBA, Manoj Maniar, PhD, Michael E. Petrone, MD MPH, Steven M. Fruchtman, MD, Lewis R. Silverman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 230.
https://doi.org/10.1182/blood-2018-99-119259
Published: 2018